Becton Dickinson and Co (BDX) Stake Raised by AE Wealth Management LLC

AE Wealth Management LLC lifted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 23.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,910 shares of the medical instruments supplier’s stock after acquiring an additional 367 shares during the quarter. AE Wealth Management LLC’s holdings in Becton Dickinson and were worth $458,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Almanack Investment Partners LLC. purchased a new stake in shares of Becton Dickinson and during the 2nd quarter worth about $105,000. Bartlett & Co. LLC boosted its stake in shares of Becton Dickinson and by 2,900.0% during the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after acquiring an additional 435 shares in the last quarter. BDO Wealth Advisors LLC boosted its stake in shares of Becton Dickinson and by 361.6% during the 1st quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock worth $125,000 after acquiring an additional 452 shares in the last quarter. Kaizen Advisory LLC boosted its stake in shares of Becton Dickinson and by 155.9% during the 2nd quarter. Kaizen Advisory LLC now owns 609 shares of the medical instruments supplier’s stock worth $146,000 after acquiring an additional 371 shares in the last quarter. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in shares of Becton Dickinson and during the 2nd quarter worth about $163,000. 86.96% of the stock is currently owned by institutional investors and hedge funds.

BDX has been the topic of a number of research reports. Wells Fargo & Co raised their price target on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Citigroup raised their price target on shares of Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $248.00 price target on shares of Becton Dickinson and in a research note on Friday, August 3rd. KeyCorp reaffirmed a “buy” rating and issued a $264.00 price target on shares of Becton Dickinson and in a research note on Friday, August 3rd. Finally, ValuEngine raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $251.64.

Shares of Becton Dickinson and stock opened at $260.63 on Friday. The stock has a market capitalization of $69.13 billion, a P/E ratio of 27.49, a P/E/G ratio of 1.76 and a beta of 1.10. Becton Dickinson and Co has a twelve month low of $191.53 and a twelve month high of $263.37. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.86 by $0.05. The firm had revenue of $4.28 billion for the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. Becton Dickinson and’s quarterly revenue was up 41.0% compared to the same quarter last year. During the same period last year, the company posted $2.46 EPS. sell-side analysts forecast that Becton Dickinson and Co will post 11.01 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 7th will be issued a $0.75 dividend. The ex-dividend date is Thursday, September 6th. This represents a $3.00 dividend on an annualized basis and a yield of 1.15%. Becton Dickinson and’s payout ratio is 31.65%.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

See Also: Trading Strategy Methods and Types

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit